Helix BioPharma (TSE:HBP) Sets New 1-Year High - What's Next?

Key Points

• Helix BioPharma Corp. reached a new 52-week high of C$5.20 during trading, closing at C$5.00 after a previous close of C$3.95.
• The company has a market cap of C$405.57 million and a price-to-earnings ratio of -5.16, indicating a focus on early-stage development.
• Helix specializes in cancer drug development, particularly in immuno-oncology, with key pipeline candidates including Tumor Defence Breaker L-DOS47 and V-DOS47.

Helix BioPharma Corp. (TSE:HBP - ) reached a new 52-week high during trading on Monday . The company traded as high as C$5.20 and last traded at C$5.00, with a volume of 37551 shares changing hands. The stock had previously closed at C$3.95.

Helix BioPharma Stock Performance

The stock has a market cap of C$405.57 million, a price-to-earnings ratio of -5.16 and a beta of 0.12. The business has a 50-day simple moving average of C$1.52 and a two-hundred day simple moving average of C$1.12.

Helix BioPharma Company Profile

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.